Alto Neuroscience (NYSE:ANRO) Earns Buy Rating from Chardan Capital

Alto Neuroscience (NYSE:ANRO)‘s stock had its “buy” rating reiterated by equities researchers at Chardan Capital in a note issued to investors on Thursday,Benzinga reports. They currently have a $30.00 price objective on the stock. Chardan Capital’s price target points to a potential upside of 28.31% from the stock’s previous close.

A number of other equities research analysts have also recently commented on the company. Wall Street Zen cut Alto Neuroscience from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Wedbush increased their price target on Alto Neuroscience from $13.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 17th. Robert W. Baird raised their price objective on Alto Neuroscience from $22.00 to $41.00 and gave the company an “outperform” rating in a report on Wednesday, March 18th. BTIG Research increased their target price on Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Alto Neuroscience in a research note on Monday, December 29th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $34.33.

Alto Neuroscience Price Performance

Shares of NYSE ANRO opened at $23.38 on Thursday. The company has a debt-to-equity ratio of 0.12, a current ratio of 15.69 and a quick ratio of 15.69. The stock has a market capitalization of $746.90 million, a price-to-earnings ratio of -10.72 and a beta of 2.52. The firm’s 50 day simple moving average is $19.09 and its 200-day simple moving average is $14.63. Alto Neuroscience has a 12 month low of $1.60 and a 12 month high of $25.17.

Alto Neuroscience (NYSE:ANRO) last posted its earnings results on Monday, March 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.11. Analysts expect that Alto Neuroscience will post -2.54 EPS for the current year.

Institutional Trading of Alto Neuroscience

Large investors have recently made changes to their positions in the company. Vanguard Personalized Indexing Management LLC lifted its holdings in Alto Neuroscience by 13.7% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock valued at $69,000 after purchasing an additional 2,055 shares in the last quarter. Peapod Lane Capital LLC lifted its stake in Alto Neuroscience by 1.1% in the 3rd quarter. Peapod Lane Capital LLC now owns 281,963 shares of the company’s stock worth $1,136,000 after purchasing an additional 3,106 shares in the last quarter. Torren Management LLC purchased a new position in Alto Neuroscience in the 4th quarter worth approximately $62,000. XTX Topco Ltd boosted its holdings in shares of Alto Neuroscience by 32.2% during the 4th quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock worth $371,000 after purchasing an additional 5,078 shares during the last quarter. Finally, Citizens Financial Group Inc. RI grew its position in shares of Alto Neuroscience by 19.0% in the third quarter. Citizens Financial Group Inc. RI now owns 40,000 shares of the company’s stock valued at $161,000 after purchasing an additional 6,394 shares in the last quarter.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.